Actively Recruiting
First-in-Human Study Evaluating Safety and Effects of GW01-200 Tablets in Adults with Advanced Tumors
Led by Groovy Medicine (Hangzhou) Ltd. · Updated on 2026-08-14
100
Participants Needed
3
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying GW01-200 tablets in a phase 1, open-label trial to assess their safety, tolerability, pharmacokinetics, and preliminary effectiveness in adults with advanced tumors, including both solid tumors and blood cancers. The study focuses on participants whose disease has progressed after standard treatments or who have no available standard treatments. Participants receive GW01-200 tablets orally at increasing dose levels to find the recommended dose for further study. The trial includes several parts where participants with advanced solid tumors or relapsedrefractory hematological malignancies are treated with specified doses to monitor effects and responses. During the study, participants will undergo assessments of adverse events, drug concentration in the body, and tumor response over up to approximately 2 years. Researchers will monitor safety, preliminary treatment effects, and pharmacokinetic properties through regular evaluations and follow-ups throughout the trial duration.
CONDITIONS
Brief Title
A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors
Research Team
Y
Yongchao Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here